U.K.-based biotech Alchemab on Tuesday announced a licensing agreement with Eli Lilly (NYSE:LLY) to jointly develop ATLX-1282, an early-stage therapeutic candidate targeting amyotrophic lateral ...

Under the terms of the agreement, Alchemab will be taking the programme through early Phase 1 clinical trials after which Lilly will lead all further development and commercialisation. Alchemab's ...

UK-based Alchemab has secured a licensing agreement worth up to $415m with Eli Lilly for ATLX-1282, its investigational antibody therapy targeting amyotrophic lateral sclerosis (ALS) and other ...

According to deal terms announced Tuesday, Lilly is licensing Alchemab’s ATLX-1282, an antibody that the companies say brings a first-in-class approach to ALS and other neurodegenerative diseases.

Under the terms of the agreement, Alchemab will be taking the programme through early phase 1 clinical trials after which Lilly will lead all further development and commercialisation. Alchemab’s ...

Just four months after Eli Lilly and British biotech Alchemab penned a discovery collaboration, the Big Pharma is licensing its first drug asset from the deal. Lilly will pay up to $415 million in ...

Eli Lilly has added another candidate to a growing pipeline of amyotrophic lateral sclerosis (ALS) therapies, tapping UK start-up Alchemab for an antibody currently being prepared for clinical ...

Eli Lilly will be licensing Alchemab Therapeutics’ preclinical programme for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases in a deal worth up to $415m. The agreement, ...